Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Lottestrasse 59, 20259, Hamburg, Germany.
Department of Trauma and Orthopaedic Surgery, Division of Orthopaedics, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Osteoporos Int. 2022 Oct;33(10):2177-2184. doi: 10.1007/s00198-022-06470-3. Epub 2022 Jun 25.
This study examined the effects of denosumab compared to bisphosphonates and vitamin D alone on muscle performance in patients with low BMD. While grip force improved in both the denosumab and bisphosphonate group, a superior increase in chair rising test force was observed in the denosumab group.
The aim of this study was to investigate the effect of the anti-resorptive agent denosumab (Dmab) on upper and lower limb muscle performance compared to bisphosphonate (BP) treatment and vitamin D supplementation alone (i.e., basic therapy) in patients with low BMD.
This retrospective, propensity score-matched (sex, age, BMI, follow-up time) cohort study included 150 osteopenic or osteoporotic patients receiving basic (n = 60), BP (n = 30) or Dmab (n = 60) therapy. All patients underwent a musculoskeletal assessment at baseline and follow-up, including DXA, laboratory bone metabolism parameters, grip force, and chair rising test mechanography. Mean annual percentage changes were calculated and compared between study groups.
After a mean follow-up period of 17.6 ± 9.0 months, a significantly higher increase in grip force in both the Dmab (p < 0.001) and BP group (p = 0.001) compared to the vitamin D group was observed (vitamin D = - 6.1 ± 10.2%; BP = + 0.8 ± 8.2%; Dmab = + 5.1 ± 25.5%). The Dmab group showed a significantly higher increase in chair rising test force compared to the BP group (vitamin D = + 5.8 ± 12.7%; BP = + 0.9 ± 8.6%; Dmab = + 8.2 ± 14.4%; Dmab vs. BP p = 0.03). Neither the changes in BMD nor in bone metabolic parameters were associated with changes in muscle performance.
Dmab resulted in increased muscle strength in the upper and lower limbs, indicating systemic rather than site-specific effects as compared to BP. Based on these findings, Dmab might be favored over other osteoporosis treatments in patients with low BMD and poor muscle strength.
本研究旨在比较抗吸收剂地舒单抗(Dmab)与双磷酸盐(BP)治疗以及单独维生素 D 补充(即基础治疗)对低骨密度患者上肢和下肢肌肉性能的影响。
这是一项回顾性、倾向评分匹配(性别、年龄、BMI、随访时间)的队列研究,纳入了 150 名患有低骨密度的骨质疏松或骨量减少患者,接受基础治疗(n=60)、BP 治疗(n=30)或 Dmab 治疗(n=60)。所有患者在基线和随访时均接受肌肉骨骼评估,包括 DXA、实验室骨代谢参数、握力和椅子上升试验力学图。计算并比较各组的年平均百分比变化。
在平均 17.6±9.0 个月的随访后,与维生素 D 组相比,Dmab 组(p<0.001)和 BP 组(p=0.001)的握力显著增加(维生素 D= -6.1±10.2%;BP= +0.8±8.2%;Dmab= +5.1±25.5%)。与 BP 组相比,Dmab 组在椅子上升试验力方面的增加更为显著(维生素 D= +5.8±12.7%;BP= +0.9±8.6%;Dmab= +8.2±14.4%;Dmab 与 BP 比较,p=0.03)。肌肉性能的变化与 BMD 或骨代谢参数的变化均无相关性。
与 BP 相比,Dmab 可增强上肢和下肢的肌肉力量,提示其具有全身而非局部作用。基于这些发现,Dmab 可能优于其他骨质疏松症治疗药物,适用于低骨密度且肌肉力量较弱的患者。